Acne
Actinic Keratosis
Aesthetics
Alopecia
Atopic Dermatitis
Buy-and-Bill
COVID-19
Case-Based Roundtable
Chronic Hand Eczema
Drug Watch
Eczema
General Dermatology
Hidradenitis Suppurativa
Melasma
NP and PA
Pediatric Dermatology
Pigmentary Disorders
Practice Management
Precision Medicine and Biologics
Prurigo Nodularis
Psoriasis
Psoriatic Arthritis
Rare Disease
Rosacea
Skin Cancer
Vitiligo
Wound Care

Updates in Pediatric Atopic Dermatitis : Episode 11

Opinion

Video

March 10, 2025

New Systemic Therapies for Pediatric Atopic Dermatitis: Nemolizumab and Oral JAK Inhibitors

Author(s):

Lisa Swanson, MD, FAAD,Lawrence Eichenfield, MD

Panelists discuss the newer systemic treatment options for pediatric atopic dermatitis (AD), including tralokinumab, JAK inhibitors, and nemolizumab, focusing on their mechanisms of action, efficacy, and safety profiles in treating moderate to severe cases of the condition in children.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP: 1.Updates in Pediatric Atopic Dermatitis

EP: 2.Pathophysiology and Role of Type 2 Inflammation in Pediatric Atopic Dermatitis

EP: 3.Talking to Patients and Families About Type 2 Inflammatory Conditions

EP: 4.Unpacking the Atopic Dermatitis Burden of Disease With Patients and Families

EP: 5.Unique Challenges in Managing Atopic Dermatitis in Pediatric Patients

EP: 6.New Nonsteroid Topical Treatments for Pediatric Atopic Dermatitis: Topical Ruxolitinib

EP: 7.New Nonsteroid Topical Treatments for Pediatric Atopic Dermatitis: Topical Roflumilast

EP: 8.New Nonsteroid Topical Treatments for Pediatric Atopic Dermatitis: Topical Tapinarof

EP: 9.New Systemic Therapies for Pediatric Atopic Dermatitis: Dupilumab and IL-13 Inhibitors

EP: 10.Understanding and Treating Pediatric AD Inside and Out

Now Viewing

EP: 11.New Systemic Therapies for Pediatric Atopic Dermatitis: Nemolizumab and Oral JAK Inhibitors

EP: 12.Future Directions for Pediatric Atopic Dermatitis Management and Research

Video content above is prompted by the following:

Moving on to systemic treatment options, let’s discuss some of the newer systemic treatment options available for pediatric AD, including mechanism of action, efficacy, and safety:

JAK inhibitors
Nemolizumab

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe Now!

Related Videos

Case 2: Poorly Managed GPP Flares and Effisayil 2 Trial Results

Case 1: Experts on a GPP Emergency Case and Effisayil 1 Trial Results

Long-Term Efficacy and Safety of IL-17 Inhibitors in Psoriasis

Determining Appropriate Candidates for JAK Inhibitor Therapy

Enhancing Treatment Adherence: The Impact of Convenience and Topical JAK Inhibitors on Real-World Outcomes

Potential Role of Ruxolitinib Cream in Managing Pediatric Atopic Dermatitis: A Perspective on Use in Ages 2–11

The Need for Nonsteroidal Alternatives in Long-Term Atopic Dermatitis Care: A Focus on Pediatric Patients

Parental Frustrations with Current Treatment Options for Children with Atopic Dermatitis

Navigating Patient Factors When Deciding Treatment for a 38-Year-Old Woman With Severe Atopic Dermatitis

Hepatic Safety of IL-17 Inhibitors in Patients With Psoriasis